VIRX viracta.com Final Profit

Corporate emblem and logo of viracta.com (VIRX)

Scaling risks for the precision medicine portfolio for lymphoma therapy are confirmed by the net income dynamics of Viracta Therapeutics (VIRX), where 0.00 captures the current state of the parameter. Automation of small molecule screening helps the company withstand pressure from industry behemoths in the field of biotech epigenetics. Robotic stations and AI-driven analysis of cellular assays accelerate the search for formulas, minimizing routine labor for scientists.

VIRX (Viracta) Net Profit history from 07/04/2022 to 02/16/2025

Analytical breakdowns and data insights for company viracta.com (VIRX)

- stock value and consensus price forecast:
Market Price Viracta Therapeutics, Inc.|VIRX - Price Target Chart
- market capitalization data:
Market Value Viracta Therapeutics, Inc.|VIRX - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Viracta Therapeutics|VIRX - Book Capitalization|Market Cap to Net Assets Ratio viracta.com|VIRX - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Viracta Therapeutics|VIRX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Viracta Therapeutics, Inc.|VIRX - Company Aggregate Debts|Debts to Book Value Viracta Therapeutics, Inc.|VIRX - Company Long-Term Liabilities|Company Short-Term Debt Viracta Therapeutics|Interim Coverage Ratio viracta.com
- net income and valuation multiples indicators:
VIRX - Company Net Income
Fundamental valuation:VIRX Viracta
Manufactured product of Viracta Therapeutics Inc.

Viracta Therapeutics' progress in developing therapies for virus-dependent cancers is reflected in the company's bottom line on the GURU.Markets platform. This indicator captures the net financial result after deducting all operating expenses, allowing investors to assess the business's actual ability to generate income while developing innovative drug combinations and to determine the asset's fundamental stability during periods of market volatility.

Key competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Income ARAY (Accuray Incorporated)|Company Net Income SLS (sellaslifesciences.com)|Net Profit ACTU (Actuate Therapeutics)|Net Financial Result Citius Oncology Inc. (CTOR)|HURA - Company Net Income|Final Profit TARA (Protara Tx)|FATE: Net Profit|Aadi Bioscience (WHWK) - Net Profit|TCRX (TScan Therapeutics Inc) - Net Profit|Net Income Champions Oncology Corp (CSBR)|Net Income XBIT (XBiotech Inc.)|Profit After Payment of Taxes CVM|Net Profit OSTX (OS Therapies Incorporated)|Net Profit Radiopharm Theranostics Ltd RADX|ARTV: Net Income|Final Profit ANL (Adlai Nortye Ltd.)|VERU (Veru Pharma) - Net Income|TPST: Profit After Payment of Taxes|XLO (Xilio Therapeutics Inc) - Net Profit|RENB: Final Profit|Net Profit MURA|KAPA - Company Net Income|Company Net Income OnKure Therapeutics OKUR|Final Profit GDTC|Curis Corp - Net Profit|APLM - Net Profit|Tharimmune (THAR) - Company Net Income|Profit After Tax ADVB (Advanced Biomed)|GNPX (Genprex, Inc) - Net Profit|Company Net Income Calidi Bio CLDI|Net Income SBFM (Sunshine Biopharma)|Net Profit xeneticbio.com (XBIO)|Salarius Pharmaceuticals, Inc. - Net Income|Profit After Payment of Taxes PPBT (Purple Biotech Ltd)|AON - Net Profit|Net Financial Result BeiGene Ltd BGNE|CKPT: Net Profit|Net Income Elevation Oncology Inc.|Company Net Income iCAD Inc.|Ikena (IKNA) - Net Financial Result|Net Income NTBL (Notable Labs Inc.)|Company Net Income MOR (MorphoSys Corporation)|Net Profit NAYA (NAYA Biosciences)|Net Financial Result ascentage.com (AAPGV)